重组人p53腺病毒注射液联合顺铂胸腹腔内注射治疗恶性胸腹水疗效观察

Abstract
Figure/Table
References
Related Citation (7)

Download: PDF (601 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the clinical value of combined application of recombinant human adenovirus p53 injected into thoracic cavity and abdominal cavity with cisplatin therapy in treating malignant thoracic cavity and abdomen cavity effusion. Methods Forty-two patients with malignant thoracic or abdomen cavity effusion in this hospital from Janurary 2010 to December 2012 were included in this study. The patients were divided into two groups: for observation group (n=21), recombinant 2?10¹² VP human adenovirus p53 injected into thoracic cavity, recombinant 4?10¹² VP human adenovirus p53 injected into abdominal cavity after outflow effusion by puncture. Patients were demanded to change their position after injection, 40 mg/m² cisplatin injection was performed after 24 hours. The injection was repeated once every week and 4 times was a therapy period. For control group (n=21), only cisplatin was used. The clinical grading, quality of life, Kashi grading, and untoward reactions were observed and recorded for all patients. Survival period was recorded at the same time. Results The efficiency rate of therapy(CR+PR+SD)for observation group was 85.7%(18/21), while that for control group was 57.1%(12/21)(P<0.05). The increase in Kashi grading of living quality was 76.2%(16/21), while that for control group was 38.1%(8/21)(P<0.05). Conclusions Combined application of recombinant human adenovirus p53 injected into thoracic cavity and abdominal cavity with cisplatin therapy in treating malignant thoracic cavity and abdomen cavity effusion shows great clinical value with mild untoward reaction.

Key words： recombinant human adenovirus p53 injection malignant thoracic cavity and abdominal cavity effusion gene therapy

Received: 25 June 2013

ZTFLH:

R57

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Feng-Ling
	LUO She-Wen
	MAO Ji-Fen
	SONG Xiao-Ping
	LIU Ming-He
	XU Li

Cite this article:

ZHAO Feng-Ling,LUO She-Wen,MAO Ji-Fen等. Clinical study of combined application of recombinant human adenovirus p53 injected into thoracic cavity and abdominal cavity with cisplatin therapy in treating malignant thoracic cavity and abdomen cavity effusion[J]. , 2014, 25(1): 48-50.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2014/V25/I1/48

[1]	秦苑, 任东, 范宇飞.腹腔内灌注重组人P53腺病毒注射液及顺铂结合局部亚高温热疗治疗恶性腹水观察[J]. 实用临床医药杂志, 2011, 15(13): 15-17.
[2]	罗社文, 高锦, 毛积分.树突状细胞联合细胞因子诱导的杀伤细胞治疗非小细胞肺癌的疗效观察[J].武警医学, 2011, 10(22): 879-882.
[2]	罗社文, 高锦, 毛积分.树突状细胞联合细胞因子诱导的杀伤细胞治疗非小细胞肺癌的疗效观察[J].武警医学, 2011, 10(22): 879-882.
[3]	陈群, 石琴, 谢强, 等.重组人血管内皮抑制素联合化疗治疗恶性胸腔积液的临床观察[J].临床肿瘤学杂志, 2008, 13(10):938-941.
[3]	陈群, 石琴, 谢强, 等.重组人血管内皮抑制素联合化疗治疗恶性胸腔积液的临床观察[J].临床肿瘤学杂志, 2008, 13(10):938-941.
[4]	严林.高聚生联合顺铂胸腔内化疗治疗恶性胸腔积液40例疗效观察[J].实用医技杂志, 2006, 13(20):3634-3635.
[4]	严林.高聚生联合顺铂胸腔内化疗治疗恶性胸腔积液40例疗效观察[J].实用医技杂志, 2006, 13(20):3634-3635.
[5]	张珊文, 肖卫群, 吕有勇. 抑癌基因p53对人胃癌细胞系放射敏感性的作用[J]. 中华放射肿瘤学杂志, 1999, 2(8): 116.
[5]	张珊文, 肖卫群, 吕有勇. 抑癌基因p53对人胃癌细胞系放射敏感性的作用[J]. 中华放射肿瘤学杂志, 1999, 2(8): 116.
[6]	彭朝辉, 肖卫群, 吕有勇. 抑癌基因p53对人胃癌细胞放射敏感性的作用[J]. 中华医学杂志, 2003, 83(23): 2008-2010.
[6]	彭朝辉, 肖卫群, 吕有勇. 抑癌基因p53对人胃癌细胞放射敏感性的作用[J]. 中华医学杂志, 2003, 83(23): 2008-2010.
[7]	Achison M, Hupp T R. Hypoxia attenuates the p53 response to celluar damage[J].Oncogene, 2003, 22(22): 3431-3440.
[7]	Achison M, Hupp T R. Hypoxia attenuates the p53 response to celluar damage[J].Oncogene, 2003, 22(22): 3431-3440.
[8]	Frank D K. Gene therapy for head and neck cancer [J].Surg Oncol Clin North Am , 2002, 11(93):607-620.
[8]	Frank D K. Gene therapy for head and neck cancer [J].Surg Oncol Clin North Am , 2002, 11(93):607-620.